These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24340637)

  • 1. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell and tissue therapy regulation: worldwide status and harmonization.
    Kellathur SN; Lou HX
    Biologicals; 2012 May; 40(3):222-4. PubMed ID: 22374355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
    Kellathur SN
    Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory barriers to tissue-engineered products.
    Schutte E
    Med Device Technol; 2002 Mar; 13(2):27-9. PubMed ID: 11984990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory issues in cell-based therapy for clinical purposes.
    Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
    Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International harmonisation of regulatory requirements.
    Holmes M; Hill RE
    Rev Sci Tech; 2007 Aug; 26(2):415-20. PubMed ID: 17892161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Good manufacturing practice: the role of local manufacturers and competent authorities.
    Tomić S; Filipović Sučić A; Ilić Martinac A
    Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European regulation for therapeutic use of stem cells.
    Ferry N
    Biomed Mater Eng; 2017; 28(s1):S3-S7. PubMed ID: 28372273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a cell-based medicinal product: regulatory structures in the European Union.
    Gálvez P; Clares B; Hmadcha A; Ruiz A; Soria B
    Br Med Bull; 2013; 105():85-105. PubMed ID: 23184855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Legal regulation in the field of tissue engineering].
    Farkas B; Bárdos T; Bellyei A; Illés T
    Orv Hetil; 2008 Jun; 149(22):1023-8. PubMed ID: 18508736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of Good Manufacturing Practice (GMP) for Biomedical Cell Products.
    Tulina MA; Pyatigorskaya NV
    Bull Exp Biol Med; 2018 Mar; 164(4):579-582. PubMed ID: 29504094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.